Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.
about
Recent advances in primary Sjogren's syndromeRituximab Effectiveness and Safety for Treating Primary Sjögren's Syndrome (pSS): Systematic Review and Meta-AnalysisEULAR Sjögren's syndrome disease activity index (ESSDAI): a user guideThe clinical relevance of animal models in Sjögren's syndrome: the interferon signature from mouse to manReviewing primary Sjögren's syndrome: beyond the dryness - From pathophysiology to diagnosis and treatmentTreatment of primary Sjögren syndrome.High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary Sjögren's Syndrome: Data from the TEARS Randomized Trial.Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis.The Diagnosis and Treatment of Sjögren's Syndrome.Manipulating autophagic processes in autoimmune diseases: a special focus on modulating chaperone-mediated autophagy, an emerging therapeutic target.Low-intensity pulsed ultrasound rescues insufficient salivary secretion in autoimmune sialadenitisAcupuncture for Primary Sjögren Syndrome (pSS) on symptomatic improvements: study protocol for a randomized controlled trial.Immunotherapy Prospects for Painful Small-fiber Sensory Neuropathies and Ganglionopathies.Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study.Antibodies against carbamylated proteins are present in primary Sjögren's syndrome and are associated with disease severity.SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome.The Core Pattern Analysis on Chinese Herbal Medicine for Sjögren's syndrome: A Nationwide Population-Based StudyChloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases.The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.Incidence and Mortality of Physician-Diagnosed Primary Sjögren Syndrome: Time Trends Over a 40-Year Period in a Population-Based US Cohort.Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.Recommendations for the treatment of Sjögren's syndrome.Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?Safety of treatments for primary Sjögren's syndrome.Present and future of biologic drugs in primary Sjögren's syndrome.Recent progress in the development of Toll-like receptor (TLR) antagonists.New Treatment Guidelines for Sjögren's Disease.Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain.Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.Sjögren Syndrome and Other Causes of Sicca in Older Adults.Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).Dry Eye Management: Targeting the Ocular Surface Microenvironment.Cutaneous and Mucosal Manifestations of Sjögren's Syndrome.Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.Cutaneous purpura of Sjögren syndrome successfully treated with hydroxychloroquine.H1N1 vaccination in Sjögren's syndrome triggers polyclonal B cell activation and promotes autoantibody production.Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial.Guidelines for treatment of primary Sjögren's syndrome: a first useful stone but still much to do.Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome.Chronic Autoimmune Epithelitis in Sjögren's Syndrome and Primary Biliary Cholangitis: A Comprehensive Review.
P2860
Q26747049-C02DE228-DC43-4707-A845-B5FEC3E810B9Q26753072-CFA50757-BDC7-4F52-B129-3A2DAC6F3262Q26778262-FB0FD28F-FD91-4601-AC9C-7DC7E8C14D1BQ26825196-90324B93-881F-4503-9EE1-28A19A1E5E85Q30234992-5D1BFB2C-41A8-403A-B079-D6193360E7DFQ30249011-7EBB2A3A-50BF-42B9-9A22-B570DDDB7BDCQ30372606-BDC4E9B6-01AC-4CF4-8027-6F1BD161D826Q33667694-3DF4616F-973C-4EB0-AE62-77AE8811F007Q33800932-D80E5A70-3E5D-49F3-BA0A-73EF17A3AD1EQ35622999-C138761C-C4A2-48FA-B278-3F9A5780E4B3Q36131422-776C8E7A-ABFE-43A8-A767-915065A35E80Q36254489-F5C61D76-E93E-4E1F-8794-DAF9502E8041Q36484460-31958574-B283-4BC5-A567-B930DB70AA61Q36989837-58B243D9-FF4E-419D-B0D5-18D72426D01EQ37156391-C0D90D19-A6A5-4DE8-92C4-61625AC877B9Q37587370-4272B5C1-1D4D-4F59-B911-D6F3F19A0469Q37744586-6248B9EF-B63A-4977-A9A5-B301C70434E9Q38360827-E03F9B45-2DF1-49FE-8D29-683F30F1657CQ38372196-E830E8D9-9964-4D1A-AD40-6223505658BCQ38401667-8C326C2F-22E9-48D4-91C4-BAE802FA38A6Q38561490-94B38870-1E9A-44FE-A0FF-318E7A37618BQ38584878-7802F247-5781-4ABE-9364-DE62A73CCBF6Q38676903-4B26FA46-3BE2-437E-B3EC-3A40B2D51577Q38711144-991779B7-8BAE-49CC-9C3E-B5BC6D351364Q38822415-0E1BD1E2-CB19-4C2B-9589-5EC19F350B7BQ38823065-886AA3D6-FDCE-480F-A4BB-5BB00F77C907Q38840388-7DE0F4F6-8A76-4EE5-9BBD-B523A95D2630Q38889818-560A3F8E-4B2F-4F92-963B-339EC460E44AQ38906337-8407C08C-7743-4F04-8AD6-517DB911EB80Q39019614-72F93D6C-9267-412B-9395-B5BE12504C7BQ39081726-11D97454-B916-4192-AC1D-DEE2568C6606Q39404635-96DED7FC-4466-4042-89D6-BA994DC47BECQ40067064-F4E099B2-BD15-41BC-8D36-8EBB8FFE2335Q40383414-65389967-0E0A-45FD-AF4C-401A9724BE3FQ41064137-45039DBF-EA16-4910-8A39-8CCA4356A7CCQ41912227-D7776406-071F-412D-B47B-D2E03D39E142Q41913718-A0CA82DD-05BE-4C10-9B8C-678C00A605B5Q41928623-91BA9E9C-C21C-4511-AF1A-4940A7B6B760Q47133516-F35CA19A-F0CA-4DA4-9E9B-111EBFD170AFQ47146987-CDBF0642-87E5-4EB9-A8CC-A77DD73F9BE1
P2860
Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Effects of hydroxychloroquine ...... UER randomized clinical trial.
@ast
Effects of hydroxychloroquine ...... UER randomized clinical trial.
@en
Effects of hydroxychloroquine ...... UER randomized clinical trial.
@nl
type
label
Effects of hydroxychloroquine ...... UER randomized clinical trial.
@ast
Effects of hydroxychloroquine ...... UER randomized clinical trial.
@en
Effects of hydroxychloroquine ...... UER randomized clinical trial.
@nl
prefLabel
Effects of hydroxychloroquine ...... UER randomized clinical trial.
@ast
Effects of hydroxychloroquine ...... UER randomized clinical trial.
@en
Effects of hydroxychloroquine ...... UER randomized clinical trial.
@nl
P2093
P50
P356
P1476
Effects of hydroxychloroquine ...... UER randomized clinical trial.
@en
P2093
Aleth Perdriger
Charles Zarnitsky
Claire Larroche
Damien Sene
Djilali Batouche
Elodie Perrodeau
Gilles Hayem
Jacques Morel
Jean Sibilia
Jean-Jacques Dubost
P304
P356
10.1001/JAMA.2014.7682
P407
P50
P577
2014-07-01T00:00:00Z